Jim Hoffman: A New Approach to Balancing Host Defense and Tissue Protection
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared Nicole Malachowski ’s post on LinkedIn about recent article by Marwa Omar et al., published in International Journal of Molecular Sciences, adding:
“NETosis is often described as being a ‘double-edged sword’, often used to describe situations where it has the potential for both positive and negative impacts on the host when combating and trying to recover from infectious insults.
Santersus AG has decided to offer a unique and very promising treatment for ‘NETosis dysregulation’ that helps patients remove tissue-damaging NETs from the blood circulation rather than interfering with the NETotic response via systemic drug administration, which can create unwanted side effects and reduce the efficacy of site-specific innate NETosis and NET removal/clearance where it is needed.
‘Most of the studies that have addressed the implications of NETs in protozoan infections have chiefly focused on their protective side, either through trapping or killing.
Challenging this belief, we propose several limitations regarding protozoan-NETs interaction.
One of many is the duality in the functional responses of NETs, in which both the positive and pathological aspects seem to be closely”
Nicole Malachowski, shared a post on LinkedIn:
“ICYMI: A new study came out last week, and it is huge.
FDA-cleared Lyme disease tests have been missing up to 78% of early Lyme cases.
It’s worse than we could have imagined.
How many people are being misdiagnosed?
How much chronic illness has developed because of this?
How much unnecessary suffering has been caused for patients and families?
We need improved diagnostics now.
Read the details from the Bay Area Lyme Foundation here:”
Title: NETosis in Parasitic Infections: A Puzzle That Remains Unsolved
Authors: Marwa Omar, Heba Abdelal
Stay updated on all scientific advances Hemostasis Today.
-
Aug 31, 2026, 14:03Adil Aftab: Anticoagulation in CKD – Key Updates from the 2026 ESC Guidelines
-
Aug 31, 2026, 14:01Isa Oboirien: Why Might Factor XI Inhibition Work Differently in Stroke and ACS?
-
Aug 31, 2026, 13:55Mike Morrissey: Advancing Europe’s Cardiovascular Health Agenda at ESC Congress 2026
-
Aug 31, 2026, 13:44Penilla Gunther: Patient Voices Take Center Stage in Cardiovascular Prevention at ESC Congress 2026
-
Aug 31, 2026, 13:42Mohamed Saleh Gomaa: Master the Latest in PE Management
-
Aug 31, 2026, 13:38Lyn Kleinbach-Reilly: A New Standard for Coagulation Testing in Neonatal Care
-
Aug 31, 2026, 13:36Rafael Gomes: Can Prasugrel Replace Ticagrelor in ACS Treatment?
-
Aug 31, 2026, 05:35Does LDL Cholesterol Influence VTE Risk? – Ordo Fraterna Fibonacci
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients